Redefining anaemia management in CKD: comparative insights on desidustat, roxadustat, and molidustat as oral HIF-PH inhibitors
Introduction: Anaemia affects over 50% of advanced chronic kidney disease (CKD) patients, increasing cardiovascular mortality. Traditional erythropoiesis-stimulating agents (ESAs) require injections and carry risks, such as hypertension and thromboembolism. Hypoxia-inducible factor prolyl hydroxylas...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Clinical Medicine |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1470211825001691 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|